Company Filing History:
1 out of 8 
1 out of 8 Years Active: 2004-2007
Title: Claudia Wohlenberg: Innovator in Biopharmaceuticals
Introduction
Claudia Wohlenberg is a prominent inventor based in Hamburg, Germany. She has made significant contributions to the field of biopharmaceuticals, particularly in the development of innovative compounds and monoclonal antibodies. With a total of 2 patents, her work has the potential to impact the treatment of various diseases.
Latest Patents
Wohlenberg's latest patents include groundbreaking inventions. The first patent focuses on transfer compounds, production, and their use. This invention relates to the use of a carboxy-terminal fragment of the Ki-67 protein as a compound for intracellular transfer and release by cells. It also encompasses transfer compounds containing the Ki-67 protein and the vectors encoding them, along with pharmaceutical compositions for treating diseases.
The second patent involves monoclonal antibodies against the human Mcm3 protein. This invention details hybridoma cell lines that produce these antibodies, along with methods for their production and use. The monoclonal antibodies are designed to detect and bind human Mcm3 specifically in various detection systems. The patent also outlines procedures for preventing and treating diseases associated with Mcm3 expression.
Career Highlights
Throughout her career, Claudia Wohlenberg has worked with notable companies in the biopharmaceutical sector. She has been associated with Dakocytomation Denmark A/S and Faustus Forschungs Cie, as well as Translational Cancer Research GmbH. Her experience in these organizations has contributed to her expertise in developing innovative medical solutions.
Collaborations
Wohlenberg has collaborated with esteemed colleagues, including Johannes Gerdes and Thomas Scholzen. These partnerships have further enhanced her research and development efforts in the field of biopharmaceuticals.
Conclusion
Claudia Wohlenberg is a distinguished inventor whose work in biopharmaceuticals is paving the way for new treatment options. Her innovative patents and collaborations reflect her commitment to advancing medical science.